Literature DB >> 2511760

Resistance to ciprofloxacin appearing during therapy.

N X Chin1, N Clynes, H C Neu.   

Abstract

The development of resistance to ciprofloxacin in nine clinical isolates of Pseudomonas aeruginosa was investigated. Isolates had increases in minimal inhibitory concentrations (MICs) from 0.25 to 16 micrograms/ml. The isolates also became resistant to ofloxacin and norfloxacin, but did not show increases in MICs to aminoglycosides, antipseudomonas penicillins, or cephalosporins. One isolate from a patient with endocarditis showed a reduction in a 43-kD outer membrane protein and simultaneous increase in the imipenem MIC. This isolate also showed impaired uptake of ciprofloxacin. Respiratory isolates from cystic fibrosis patients did not show loss of outer membrane protein. MICs were lowered by ethylene diaminetetra-acetic acid, suggesting changes in lipopolysaccharide. Resistant isolates were synergistically inhibited by combinations of ciprofloxacin plus tobramycin or ceftazidime, but MICs remained beyond the achievable serum level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511760     DOI: 10.1016/0002-9343(89)90015-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Resistance to pefloxacin in Pseudomonas aeruginosa.

Authors:  M Michea-Hamzehpour; C Lucain; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa.

Authors:  M Michéa-Hamzehpour; Y X Furet; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

3.  Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.

Authors:  J A García-Rodríguez; M J Fresnadillo; M I García; E García-Sánchez; J E García-Sánchez; I Trujillano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

4.  Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States.

Authors:  C Thornsberry
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 5.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

6.  In vitro stepwise selection of resistance to quinolones, beta-lactams and amikacin in nosocomial gram-negative bacilli.

Authors:  M Michéa-Hamzehpour; A Kahr; J C Pechère
Journal:  Infection       Date:  1994       Impact factor: 3.553

7.  nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa.

Authors:  H Fukuda; M Hosaka; S Iyobe; N Gotoh; T Nishino; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 8.  Do we need an intravenous fluoroquinolone?

Authors:  D S Maddix; L Warner
Journal:  West J Med       Date:  1992-07

9.  In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.

Authors:  S A Marshall; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.